Analysis Tools
normal phenotype
|
• viable and fertile with no morphological abnormalities
|
|
Allele Symbol Allele Name Allele ID |
Stk3tm1.1Yy targeted mutation 1.1, Yingzi Yang MGI:4422170 |
||||||||||||||||||||||||||||||||||||
| Summary |
8 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• viable and fertile with no morphological abnormalities
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• following adenoviral cre injection mice are completely protected from TNF alpha or Jo-2 antibody (a Fas agonist) induced mortality
|
|
• following adenoviral cre injection mice are completely protected from TNF alpha induced liver damage
|
|
• following adenoviral cre injection mice are protected from TNF alpha or Jo-2 antibody (a Fas agonist) induced apoptosis
|
|
• following adenoviral cre injection mice are protected from TNF alpha induced increases in ALT levels
|
|
• following adenoviral cre injection mice are protected from TNF alpha induced increases in ALT levels
|
|
• following adenoviral cre injection mice are protected from TNF alpha induced liver damage
|
|
• following adenoviral cre injection mice are protected from TNF alpha or Jo-2 antibody (a Fas agonist) induced apoptosis
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• at 1 - 7 months after tamoxifen treatment
|
|
• some mice treated with tamoxifen at birth develop cholangiocarcinomas composed of mainly multilayered biliary epithelial cells
|
|
• all mice treated with tamoxifen at birth develop tumors which display characteristics of hepatocellular carcinoma by 6 months of age
|
|
• some mice treated with tamoxifen at birth develop cholangiocarcinomas composed of mainly multilayered biliary epithelial cells
|
|
• all mice treated with tamoxifen at birth develop tumors which display characteristics of hepatocellular carcinoma by 6 months of age
|
|
• some mice treated with tamoxifen at birth develop cholangiocarcinomas composed of mainly multilayered biliary epithelial cells
|
|
• in some mice at 1 - 7 months after tamoxifen treatment
|
|
• at 1 - 7 months after tamoxifen treatment
|
|
• in some mice at 1 - 7 months after tamoxifen treatment
|
|
• in some mice at 1 - 7 months after tamoxifen treatment
|
|
• in some mice at 1 - 7 months after tamoxifen treatment
|
|
• at 1 - 7 months after tamoxifen treatment
|
|
• in some mice at 1 - 7 months after tamoxifen treatment
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• slight
|
|
• dysplasia at 1 month of age
• increase in hepatocyte cell density
|
|
• at 1 month of age
|
|
• smaller
• some cells have vacuolated cytoplasm
|
|
• slight
|
|
• at 1 month of age
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• shorter skeletal elements in the limbs
|
|
• shorter skeletal elements in the limbs
|
|
• cell size appears smaller and cell density is increased in the limb cartilage
|
|
• proliferating cells are detected in the hypertrophic zone
• apoptosis is decreased compared to controls
• despite the increase in proliferation and decrease in apoptosis cartilage size is not increased
|
|
• increase in proliferation of cells in the developing limb
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• die between E9.5 and E11.5
|
|
• multiple developmental defects at E9.5 - E10.5
|
|
• at E9.5-E10.5
|
|
• MEFs are resistant to TNF alpha induced apoptosis
|
|
• resistant to TNF alpha induced apoptosis
|
|
• resistant to TNF alpha induced apoptosis
|
|
• at E9.5-E10.5
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• at 12 months of age tumors develop in 2 of 31 mice
|
|
• in untreated mice
|
|
• in untreated mice
|
|
• at 12 months of age tumors develop in 2 of 31 mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• following adenoviral cre injection mice are protected from TNF alpha or Jo-2 antibody (a Fas agonist) induced mortality
|
|
• following adenoviral cre injection mice are protected from TNF alpha induced liver damage
|
|
• following adenoviral cre injection mice are protected from TNF alpha or Jo-2 antibody (a Fas agonist) induced apoptosis
|
|
• following adenoviral cre injection mice are mostly protected from TNF alpha induced increases in ALT levels
|
|
• following adenoviral cre injection mice are mostly protected from TNF alpha induced increases in ALT levels
|
|
• following adenoviral cre injection mice are protected from TNF alpha induced liver damage
|
|
• following adenoviral cre injection mice are protected from TNF alpha or Jo-2 antibody (a Fas agonist) induced apoptosis
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 04/23/2024 MGI 6.23 |
|
|
|
||